

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/656,140
Filing Date	September 8, 2003
First Named Inventor	Tao
Group Art Unit	1633
Examiner Name	Kevin Kai HILL
Attorney Docket Number	001107.00388

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear
		5,877,309	03-02-1999	McKay & Dean	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chen <i>et al.</i> , "A Safety and Pharmacokinetic Study of a Mixed-Backbone Oligonucleotide (GEM231) Targeting the Type I Protein Kinase A by Two-hour Infusions in Patients with Refractory Solid Tumors," <i>Clin. Cancer Research</i> 6, 1259-66, April 2000	
		Clark <i>et al.</i> , "Clinical use of streptolysin-O to facilitate antisense oligodeoxynucleotide delivery for purging autografts in chronic myeloid leukaemia," <i>Bone Marrow Transplantation</i> 23, 1303-08, 1999	
		Cunningham <i>et al.</i> , "A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer," <i>Clin. Cancer Res.</i> 6, 1626-31, May 2000	
		de Smet <i>et al.</i> , "Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis," <i>Ocul. Immunol. Inflamm.</i> 7, 189-98, December 1999 (abstract)	
		Gewirtz, "Myb targeted therapeutics for the treatment of human malignancies," <i>Oncogene</i> 18, 3056-62, May 13, 1999 (abstract)	
		Glover <i>et al.</i> , "Phase I Safety and Pharmacokinetic Profile of an Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS-2302)," <i>J. Pharmacol. Exptl. Ther.</i> 282, 1173-80, 1997	
		Nemunaitis <i>et al.</i> , "Phase I Evaluation of ISIS 3521, an antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients with Advanced Cancer," <i>J. Clin. Oncol.</i> 17, 3586-95, November 1999	
		O'Dwyer <i>et al.</i> , "c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A)," <i>Clin. Cancer Res.</i> 5, 3977-82, December 1999	
		Sereni <i>et al.</i> , "Pharmacokinetics and tolerability of intravenous foscarnivir (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects," <i>J. Clin. Pharmacol.</i> 39, 47-51, January 1999 (abstract)	
		Stevenson <i>et al.</i> , "Phase I clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)," <i>J. Clin. Oncol.</i> 17, 2227-36, July 1999	
		Waters <i>et al.</i> , "Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin's Lymphoma," <i>J. Clin. Oncol.</i> 18, 1812-23, May 2000	
		Yuen <i>et al.</i> , "Phase I Study of an Antisense Oligonucleotide to Protein Kinase C- α (ISIS 3521/CGP 64128A) in Patients with Cancer," <i>Clin. Cancer Res.</i> 5, 3357-63, November 1999	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.